Cargando…
The Impact of Different Screening Model Structures on Cervical Cancer Incidence and Mortality Predictions: The Maximum Clinical Incidence Reduction (MCLIR) Methodology
Background. To interpret cervical cancer screening model results, we need to understand the influence of model structure and assumptions on cancer incidence and mortality predictions. Cervical cancer cases and deaths following screening can be attributed to 1) (precancerous or cancerous) disease tha...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7322998/ https://www.ncbi.nlm.nih.gov/pubmed/32486894 http://dx.doi.org/10.1177/0272989X20924007 |
_version_ | 1783551744388628480 |
---|---|
author | de Kok, Inge M. C. M. Burger, Emily A. Naber, Steffie K. Canfell, Karen Killen, James Simms, Kate Kulasingam, Shalini Groene, Emily Sy, Stephen Kim, Jane J. van Ballegooijen, Marjolein |
author_facet | de Kok, Inge M. C. M. Burger, Emily A. Naber, Steffie K. Canfell, Karen Killen, James Simms, Kate Kulasingam, Shalini Groene, Emily Sy, Stephen Kim, Jane J. van Ballegooijen, Marjolein |
author_sort | de Kok, Inge M. C. M. |
collection | PubMed |
description | Background. To interpret cervical cancer screening model results, we need to understand the influence of model structure and assumptions on cancer incidence and mortality predictions. Cervical cancer cases and deaths following screening can be attributed to 1) (precancerous or cancerous) disease that occurred after screening, 2) disease that was present but not screen detected, or 3) disease that was screen detected but not successfully treated. We examined the relative contributions of each of these using 4 Cancer Intervention and Surveillance Modeling Network (CISNET) models. Methods. The maximum clinical incidence reduction (MCLIR) method compares changes in the number of clinically detected cervical cancers and mortality among 4 scenarios: 1) no screening, 2) one-time perfect screening at age 45 that detects all existing disease and delivers perfect (i.e., 100% effective) treatment of all screen-detected disease, 3) one-time realistic-sensitivity cytological screening and perfect treatment of all screen-detected disease, and 4) one-time realistic-sensitivity cytological screening and realistic-effectiveness treatment of all screen-detected disease. Results. Predicted incidence reductions ranged from 55% to 74%, and mortality reduction ranged from 56% to 62% within 15 years of follow-up for scenario 4 across models. The proportion of deaths due to disease not detected by screening differed across the models (21%–35%), as did the failure of treatment (8%–16%) and disease occurring after screening (from 1%–6%). Conclusions. The MCLIR approach aids in the interpretation of variability across model results. We showed that the reasons why screening failed to prevent cancers and deaths differed between the models. This likely reflects uncertainty about unobservable model inputs and structures; the impact of this uncertainty on policy conclusions should be examined via comparing findings from different well-calibrated and validated model platforms. |
format | Online Article Text |
id | pubmed-7322998 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-73229982020-07-09 The Impact of Different Screening Model Structures on Cervical Cancer Incidence and Mortality Predictions: The Maximum Clinical Incidence Reduction (MCLIR) Methodology de Kok, Inge M. C. M. Burger, Emily A. Naber, Steffie K. Canfell, Karen Killen, James Simms, Kate Kulasingam, Shalini Groene, Emily Sy, Stephen Kim, Jane J. van Ballegooijen, Marjolein Med Decis Making Original Articles Background. To interpret cervical cancer screening model results, we need to understand the influence of model structure and assumptions on cancer incidence and mortality predictions. Cervical cancer cases and deaths following screening can be attributed to 1) (precancerous or cancerous) disease that occurred after screening, 2) disease that was present but not screen detected, or 3) disease that was screen detected but not successfully treated. We examined the relative contributions of each of these using 4 Cancer Intervention and Surveillance Modeling Network (CISNET) models. Methods. The maximum clinical incidence reduction (MCLIR) method compares changes in the number of clinically detected cervical cancers and mortality among 4 scenarios: 1) no screening, 2) one-time perfect screening at age 45 that detects all existing disease and delivers perfect (i.e., 100% effective) treatment of all screen-detected disease, 3) one-time realistic-sensitivity cytological screening and perfect treatment of all screen-detected disease, and 4) one-time realistic-sensitivity cytological screening and realistic-effectiveness treatment of all screen-detected disease. Results. Predicted incidence reductions ranged from 55% to 74%, and mortality reduction ranged from 56% to 62% within 15 years of follow-up for scenario 4 across models. The proportion of deaths due to disease not detected by screening differed across the models (21%–35%), as did the failure of treatment (8%–16%) and disease occurring after screening (from 1%–6%). Conclusions. The MCLIR approach aids in the interpretation of variability across model results. We showed that the reasons why screening failed to prevent cancers and deaths differed between the models. This likely reflects uncertainty about unobservable model inputs and structures; the impact of this uncertainty on policy conclusions should be examined via comparing findings from different well-calibrated and validated model platforms. SAGE Publications 2020-06-03 2020-05 /pmc/articles/PMC7322998/ /pubmed/32486894 http://dx.doi.org/10.1177/0272989X20924007 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Articles de Kok, Inge M. C. M. Burger, Emily A. Naber, Steffie K. Canfell, Karen Killen, James Simms, Kate Kulasingam, Shalini Groene, Emily Sy, Stephen Kim, Jane J. van Ballegooijen, Marjolein The Impact of Different Screening Model Structures on Cervical Cancer Incidence and Mortality Predictions: The Maximum Clinical Incidence Reduction (MCLIR) Methodology |
title | The Impact of Different Screening Model Structures on Cervical Cancer Incidence and Mortality Predictions: The Maximum Clinical Incidence Reduction (MCLIR) Methodology |
title_full | The Impact of Different Screening Model Structures on Cervical Cancer Incidence and Mortality Predictions: The Maximum Clinical Incidence Reduction (MCLIR) Methodology |
title_fullStr | The Impact of Different Screening Model Structures on Cervical Cancer Incidence and Mortality Predictions: The Maximum Clinical Incidence Reduction (MCLIR) Methodology |
title_full_unstemmed | The Impact of Different Screening Model Structures on Cervical Cancer Incidence and Mortality Predictions: The Maximum Clinical Incidence Reduction (MCLIR) Methodology |
title_short | The Impact of Different Screening Model Structures on Cervical Cancer Incidence and Mortality Predictions: The Maximum Clinical Incidence Reduction (MCLIR) Methodology |
title_sort | impact of different screening model structures on cervical cancer incidence and mortality predictions: the maximum clinical incidence reduction (mclir) methodology |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7322998/ https://www.ncbi.nlm.nih.gov/pubmed/32486894 http://dx.doi.org/10.1177/0272989X20924007 |
work_keys_str_mv | AT dekokingemcm theimpactofdifferentscreeningmodelstructuresoncervicalcancerincidenceandmortalitypredictionsthemaximumclinicalincidencereductionmclirmethodology AT burgeremilya theimpactofdifferentscreeningmodelstructuresoncervicalcancerincidenceandmortalitypredictionsthemaximumclinicalincidencereductionmclirmethodology AT nabersteffiek theimpactofdifferentscreeningmodelstructuresoncervicalcancerincidenceandmortalitypredictionsthemaximumclinicalincidencereductionmclirmethodology AT canfellkaren theimpactofdifferentscreeningmodelstructuresoncervicalcancerincidenceandmortalitypredictionsthemaximumclinicalincidencereductionmclirmethodology AT killenjames theimpactofdifferentscreeningmodelstructuresoncervicalcancerincidenceandmortalitypredictionsthemaximumclinicalincidencereductionmclirmethodology AT simmskate theimpactofdifferentscreeningmodelstructuresoncervicalcancerincidenceandmortalitypredictionsthemaximumclinicalincidencereductionmclirmethodology AT kulasingamshalini theimpactofdifferentscreeningmodelstructuresoncervicalcancerincidenceandmortalitypredictionsthemaximumclinicalincidencereductionmclirmethodology AT groeneemily theimpactofdifferentscreeningmodelstructuresoncervicalcancerincidenceandmortalitypredictionsthemaximumclinicalincidencereductionmclirmethodology AT systephen theimpactofdifferentscreeningmodelstructuresoncervicalcancerincidenceandmortalitypredictionsthemaximumclinicalincidencereductionmclirmethodology AT kimjanej theimpactofdifferentscreeningmodelstructuresoncervicalcancerincidenceandmortalitypredictionsthemaximumclinicalincidencereductionmclirmethodology AT vanballegooijenmarjolein theimpactofdifferentscreeningmodelstructuresoncervicalcancerincidenceandmortalitypredictionsthemaximumclinicalincidencereductionmclirmethodology AT dekokingemcm impactofdifferentscreeningmodelstructuresoncervicalcancerincidenceandmortalitypredictionsthemaximumclinicalincidencereductionmclirmethodology AT burgeremilya impactofdifferentscreeningmodelstructuresoncervicalcancerincidenceandmortalitypredictionsthemaximumclinicalincidencereductionmclirmethodology AT nabersteffiek impactofdifferentscreeningmodelstructuresoncervicalcancerincidenceandmortalitypredictionsthemaximumclinicalincidencereductionmclirmethodology AT canfellkaren impactofdifferentscreeningmodelstructuresoncervicalcancerincidenceandmortalitypredictionsthemaximumclinicalincidencereductionmclirmethodology AT killenjames impactofdifferentscreeningmodelstructuresoncervicalcancerincidenceandmortalitypredictionsthemaximumclinicalincidencereductionmclirmethodology AT simmskate impactofdifferentscreeningmodelstructuresoncervicalcancerincidenceandmortalitypredictionsthemaximumclinicalincidencereductionmclirmethodology AT kulasingamshalini impactofdifferentscreeningmodelstructuresoncervicalcancerincidenceandmortalitypredictionsthemaximumclinicalincidencereductionmclirmethodology AT groeneemily impactofdifferentscreeningmodelstructuresoncervicalcancerincidenceandmortalitypredictionsthemaximumclinicalincidencereductionmclirmethodology AT systephen impactofdifferentscreeningmodelstructuresoncervicalcancerincidenceandmortalitypredictionsthemaximumclinicalincidencereductionmclirmethodology AT kimjanej impactofdifferentscreeningmodelstructuresoncervicalcancerincidenceandmortalitypredictionsthemaximumclinicalincidencereductionmclirmethodology AT vanballegooijenmarjolein impactofdifferentscreeningmodelstructuresoncervicalcancerincidenceandmortalitypredictionsthemaximumclinicalincidencereductionmclirmethodology |